Procter & Gamble (PGHL) | Financial Analysis & Statements
Procter & Gamble Health Ltd. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
3.4B
Gross Profit
2.4B
72.25%
Operating Income
849.0M
25.06%
Net Income
661.8M
19.54%
EPS (Diluted)
₹39.87
Balance Sheet Metrics
Total Assets
7.9B
Total Liabilities
2.6B
Shareholders Equity
5.4B
Debt to Equity
0.48
Cash Flow Metrics
Operating Cash Flow
711.0M
Free Cash Flow
459.9M
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2024
Procter & Gamble Income Statement From 2018 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2018 |
|---|---|---|---|---|---|
| Revenue | 11.3B | 12.3B | 11.1B | 9.9B | 8.2B |
| Cost of Goods Sold | 3.6B | 3.6B | 3.4B | 3.4B | 2.9B |
| Gross Profit | 7.7B | 8.7B | 7.7B | 6.5B | 5.3B |
| Gross Margin % | 68.2% | 70.6% | 69.5% | 66.0% | 65.2% |
| Operating Expenses | |||||
| Research & Development | 38.6M | - | 65.5M | 39.3M | 20.5M |
| Selling, General & Administrative | 876.3M | - | 1.5B | 1.3B | 1.2B |
| Other Operating Expenses | 1.8B | 3.4B | 3.4B | 1.3B | 1.5B |
| Total Operating Expenses | 2.7B | 3.4B | 4.9B | 2.7B | 2.8B |
| Operating Income | 2.8B | 3.0B | 2.4B | 2.3B | 1.3B |
| Operating Margin % | 24.7% | 24.1% | 21.7% | 22.7% | 15.6% |
| Non-Operating Items | |||||
| Interest Income | 117.3M | - | 110.7M | 150.6M | 171.9M |
| Interest Expense | 7.2M | 7.7M | 4.2M | 8.0M | - |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 2.7B | 3.1B | 2.5B | 2.3B | 1.6B |
| Income Tax | 723.4M | 847.3M | 608.5M | 564.8M | 562.4M |
| Effective Tax Rate % | 26.5% | 27.0% | 24.0% | 24.2% | 35.6% |
| Net Income | 2.0B | 2.3B | 1.9B | 1.8B | 8.4B |
| Net Margin % | 17.8% | 18.7% | 17.3% | 17.8% | 102.5% |
| Key Metrics | |||||
| EBITDA | 3.2B | 3.4B | 2.8B | 2.7B | 1.5B |
| EPS (Basic) | ₹121.00 | ₹138.23 | ₹115.98 | ₹107.00 | ₹505.00 |
| EPS (Diluted) | ₹121.00 | ₹138.23 | ₹115.98 | ₹107.00 | ₹505.00 |
| Basic Shares Outstanding | 16599382 | 16600593 | 16599414 | 16599382 | 16599382 |
| Diluted Shares Outstanding | 16599382 | 16600593 | 16599414 | 16599382 | 16599382 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Procter & Gamble Balance Sheet From 2018 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2018 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 2.4B | 4.4B | 3.2B | 4.6B | 11.2B |
| Short-term Investments | 192.3M | 177.3M | 125.9M | 108.4M | 1.2B |
| Accounts Receivable | 853.3M | 1.2B | 834.4M | 598.1M | 661.7M |
| Inventory | 1.1B | 1.3B | 1.2B | 1.2B | 1.1B |
| Other Current Assets | 613.3M | 911.4M | 746.7M | 730.0M | 851.3M |
| Total Current Assets | 5.2B | 8.0B | 6.1B | 7.3B | 15.3B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.3B | 1.4B | 1.1B | 1.0B | 0 |
| Goodwill | 9.6M | 9.4M | 400.0K | 1.2M | 4.3M |
| Intangible Assets | 9.6M | - | 400.0K | 1.2M | 4.3M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 18.9M | 93.0M | -6.9M | -96.0M | -100.0K |
| Total Non-Current Assets | 2.7B | 3.1B | 2.8B | 2.6B | 2.3B |
| Total Assets | 7.9B | 11.0B | 8.9B | 9.9B | 17.6B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 1.7B | 2.4B | 1.8B | 1.8B | 914.2M |
| Short-term Debt | 26.8M | 31.2M | 28.3M | 47.5M | 65.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 125.3M | 89.2M | 92.4M | 82.4M | 1.9M |
| Total Current Liabilities | 2.2B | 3.0B | 2.4B | 2.4B | 1.9B |
| Non-Current Liabilities | |||||
| Long-term Debt | 68.8M | 88.8M | 0 | 28.6M | - |
| Deferred Tax Liabilities | - | - | - | - | 87.4M |
| Other Non-Current Liabilities | 6.9M | 6.5M | 6.0M | 5.7M | 28.5M |
| Total Non-Current Liabilities | 372.1M | 464.0M | 414.0M | 434.8M | 265.4M |
| Total Liabilities | 2.6B | 3.5B | 2.8B | 2.8B | 2.2B |
| Equity | |||||
| Common Stock | 166.0M | 166.0M | 166.0M | 166.0M | 166.0M |
| Retained Earnings | 1.6B | - | 2.4B | 3.3B | 11.7B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 5.4B | 7.5B | 6.2B | 7.0B | 15.4B |
| Key Metrics | |||||
| Total Debt | 95.6M | 120.0M | 28.3M | 76.1M | 65.3M |
| Working Capital | 3.1B | 4.9B | 3.8B | 4.9B | 13.4B |
Balance Sheet Composition
Procter & Gamble Cash Flow Statement From 2018 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2018 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 2.7B | 3.1B | 2.5B | 2.3B | 11.4B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 6.9M | 5.6M | 34.1M | 19.3M | - |
| Working Capital Changes | 594.9M | -939.4M | -408.0M | 394.1M | -771.8M |
| Operating Cash Flow | 3.2B | 2.1B | 2.0B | 2.6B | 10.4B |
| Investing Activities | |||||
| Capital Expenditures | -217.3M | -424.8M | -379.2M | -525.8M | -265.4M |
| Acquisitions | - | - | - | - | 10.5B |
| Investment Purchases | - | - | - | - | -1.8B |
| Investment Sales | - | - | - | 0 | 3.9B |
| Investing Cash Flow | -194.9M | -356.9M | -354.2M | -493.5M | 12.5B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -4.1B | -937.9M | -2.8B | -3.8B | -249.7M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -4.1B | -937.9M | -2.8B | -3.8B | -301.2M |
| Free Cash Flow | 2.1B | 1.9B | 1.3B | 1.9B | -1.6B |
| Net Change in Cash | -1.1B | 757.3M | -1.2B | -1.7B | 22.6B |
Cash Flow Trend
Procter & Gamble Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
36.48
Forward P/E
27.46
Price to Book
13.94
Price to Sales
6.41
PEG Ratio
-2.49
Profitability Ratios
Profit Margin
21.76%
Operating Margin
27.97%
Return on Equity
37.34%
Return on Assets
25.30%
Financial Health
Current Ratio
2.87
Debt to Equity
1.00
Beta
0.09
Per Share Data
EPS (TTM)
₹142.69
Book Value per Share
₹373.35
Revenue per Share
₹812.40
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PGHL | 86.4B | 36.48 | 13.94 | 37.34% | 21.76% | 1.00 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Piramal Pharma | 199.7B | 269.79 | 2.47 | 1.12% | -1.84% | 60.08 |
| Eris Lifesciences | 193.4B | 44.25 | 6.15 | 10.75% | 14.06% | 68.19 |
| Neuland Laboratories | 184.8B | 103.42 | 11.41 | 17.06% | 2.29% | 16.33 |
Financial data is updated regularly. All figures are in the company's reporting currency.





